Motavizumab, nirsevimab, palivizumab beneficial for RSV prevention
Significant benefits are seen with motavizumab, nirsevimab, and palivizumab for prevention of respiratory syncytial virus (RSV) in infants and children, according to a review published online Feb. 17 in JAMA Network Open.